HilleVax (HLVX) Q3 2024 earnings summary

Executive summary

• HilleVax is a clinical-stage biopharmaceutical company focused on norovirus vaccines, with no approved products or revenue to date.

• Top-line data from the NEST-IN1 Phase 2b trial for HIL-214 in infants failed to meet its primary endpoint, leading to discontinuation of HIL-214 development and significant workforce reductions.

• Reported third quarter 2024 financial results, highlighting continued development of norovirus vaccine candidates and exploration of strategic alternatives.

• The company repaid all outstanding debt in July 2024 and is exploring strategic alternatives for its remaining vaccine candidates.

• As of September 30, 2024, cash, cash equivalents, and marketable securities totaled $189.3 million.

Financial highlights

• Q3 2024 research and development expenses were $20.2 million, down year-over-year mainly due to lower HIL-214 clinical costs.

• General and administrative expenses for Q3 2024 were $6.2 million, a decrease from the prior year.

• Net loss for Q3 2024 was $25.8 million, and for the nine months ended September 30, 2024, was $113.3 million.

• Impairment charges of $8.2 million were recorded in the nine months ended September 30, 2024, due to asset write-downs following the failed trial.

• Net cash used in operating activities for the nine months ended September 30, 2024, was $90.6 million.

Outlook and guidance

• Existing cash and marketable securities are expected to fund operations for at least the next 12 months.

• No revenue is expected until successful development and approval of a vaccine candidate, which is not anticipated in the near term.

• The company is evaluating continued development of other norovirus vaccine candidates and strategic alternatives, including business development.